The beginning of the end for cancer

                 The emergence of real-time diagnostics for complex diseases will mark the beginning of the end of their debilitating reign by 2020. The ability to monitor cancer, the dynamic immune system, intestinal flora and pre-diabetes in real-time will change the nature of medicine and usher in a new era of human health where wellness is protected versus illness treated. As a result, fundamental shifts in healthcare will occur, causing it to become largely preventative rather than fire-fighting.

             These are exciting times for cancer immunotherapy. After many years of disappointing results, the tide has finally changed and immunotherapy has become a clinically validated treatment for many cancers. Immunotherapeutic strategies include cancer vaccines, oncolytic viruses, adoptive transfer of ex vivo activated T and natural killer cells, and administration of antibodies or recombinant proteins that either costimulate cells or block the so-called immune checkpoint pathways.

              The recent success of several immunotherapeutic regimes, such as monoclonal antibody blocking of cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD1), has boosted the development of this treatment modality, with the consequence that new therapeutic targets and schemes which combine various immunological agents are now being described at a breathtaking pace.